Abstract:β-Trcp (β-transducin repeat-containing protein), which is substrate-recognition subunit of SCF (SKP1-Cullin1-F-box protein) E3 ligase complexes, plays critical roles in tumorigenesis through ubiquitination and degradation of target proteins. FOX family is a transcription factor involved in organ development and tumorigenesis. Our previous study showed that FOXN2 may be a candidate substrate of β-Trcp. However, it remains largely unknown the radiosensitization effects of FOXN2 and the underlying mechanism in lung cancer cells. Co-immunoprecipitation (Co-Ip) was used to detect the interaction between FOXN2 and β-Trcp1. Ubiquitination assay was used to determine the ubiquitination site of FOXN2 by β-Trcp1. We conducted half-life experiment to determine the degradation rate of FOXN2 and its mutant form (FOXN2-AA) proteins. Using SiRNA technology, we evaluated the effect of FOXN2 on growth and proliferation in lung cancer cells. Colony formation assay and γ-H2AX foci experiment were conducted to assess the radiosensitivity of FOXN2 in lung cancer cells. We demonstrate that FOXN2 interacts with β-Trcp1 and the stability of FOXN2 is negatively controlled by β-Trcp1. Furthermore, FOXN2 is ubiquitinated by β-Trcp1 at the Ser365 and Ser369 site. Moreover, depletion of FOXN2 promotes the proliferation and radioresistance of lung cancer cells. Most importantly, mutant form of FOXN2 (FOXN2-AA) exhibits more potent inhibition ability of cancer cell proliferation and radioresistance. Our results demonstrate that FOXN2 is a new substrate of SCFβ-Trcp and degraded through ubiquitin-proteasome pathway. FOXN2 may act as a tumor suppressor gene in lung cancer cell, which inhibits the cell proliferation and enhances radiosensitivity. Taken together, our findings indicate that the upregulation of FOXN2 may be an underlying therapeutic and radiosensitization target for lung cancer.

Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis

Targeting Nrf2/PHKG2 Axis to Enhance Radiosensitivity in NSCLC.

E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination

FBXO25 Promotes Cell Proliferation, Invasion, and Migration of NSCLC

Targeting senescence-like fibroblasts radiosensitizes non–small cell lung cancer and reduces radiation-induced pulmonary fibrosis

USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription

FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer

Β-Trcp Ubiquitin Ligase and RSK2 Kinase-Mediated Degradation of FOXN2 Promotes Tumorigenesis and Radioresistance in Lung Cancer

FOXA1, induced by RC48, regulates HER2 transcription to enhance the tumorigenic capacity of lung cancer through PI3K/AKT pathway

FBXO31 Promotes Cell Proliferation, Metastasis and Invasion in Lung Cancer.

Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells.

FBXO22 Mediates Polyubiquitination and Inactivation of LKB1 to Promote Lung Cancer Cell Growth

USP9X-mediated REV1 deubiquitination promotes lung cancer radioresistance via the action of REV1 as a Rad18 molecular scaffold for cystathionine γ-lyase

FBXL2 Counteracts Grp94 to Destabilize EGFR and Inhibit EGFR-driven NSCLC Growth

FBXO28 promotes the malignancy of non-small cell lung cancer through ubiquitination-mediated activation of BRD4

Exosomal miR‐196a‐5p enhances radioresistance in lung cancer cells by downregulating NFKBIA

UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation

Poster Viewingβ-Trcp-mediated Degradation of FOXN2 Promotes Cell Proliferation and Radioresistance of Lung Cancer Cells

Foxm1 Mediated Resistance to Gefitinib in Non-Small-Cell Lung Cancer Cells

Upregulation of CoQ shifts ferroptosis dependence from GPX4 to FSP1 in acquired radioresistance

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer